AU Patent

AU2023270343B2 — Implants with controlled drug delivery features and methods of using same

Assigned to Glaukos Corp · Expires 2025-10-09 · 1y expired

What this patent protects

A drug delivery ocular implant comprising: an outer shell having a first end and a second end, the outer shell being shaped to define an interior lumen; a cap comprising a central aperture defining a region of drug release, the cap fitted to the first end of the outer shell, the …

USPTO Abstract

A drug delivery ocular implant comprising: an outer shell having a first end and a second end, the outer shell being shaped to define an interior lumen; a cap comprising a central aperture defining a region of drug release, the cap fitted to the first end of the outer shell, the region of drug release configured to elute a drug; and a membrane comprising elastic properties configured to retain the cap onto the outer shell.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023270343B2
Jurisdiction
AU
Classification
—
Expires
2025-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Glaukos Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.